VolitionRX Ltd (VNRX)

In October 2025, VolitionRx closed an underwritten public offering. In November 2025, an over-allotment for the public offering was exercised. In December 2025, the company's Nu.Q® NETs assay was included in a French government-backed program, and it received its first commercial order for Nu.Q® Cancer assays. In January 2026, VolitionRx secured non-dilutive funding from Belgian government agencies, began preparing a reimbursement submission for Nu.Q® Cancer assays in France, and reported positive results from a clinical study on its Nu.Q® Vet Feline assay. In February 2026, VolitionRx received a non-compliance notice from the NYSE American LLC and appointed a distributor for Nu.Q® Discover assays in Japan and highlighted commercial momentum. In March 2026, VolitionRx completed validation of a chemiluminescent immunoassay version of the Nu.Q® Vet Cancer Test with Fujifilm Vet Systems in Japan, released its fiscal year 2025 financial results, and disclosed a "going concern" risk, scheduling a special meeting for a reverse stock split. In April 2026, the company continued to announce its fiscal year 2025 financial results and business updates.

There is no specific information regarding demand seasonality for VolitionRx Ltd.'s products and services. Demand is likely consistent due to the medical necessity of diagnostic tests for serious diseases.

VolitionRx Limited is a multi-national epigenetics company focused on developing and commercializing nucleosome-based blood tests for early disease detection and monitoring in humans and animals. The company operates in the Healthcare sector, specifically in Diagnostics, and is categorized under Medical Devices, In Vitro & in Vivo Diagnostic Substances, and Surgical and Medical Instrument Manufacturing. Its core technology is the Nu.Q® platform, which includes Nu.Q® Cancer assays for cancer detection, Nu.Q® NETs assays for sepsis detection, Nu.Q® Discover for supplying biomarkers, Capture-Seq™ for cancer testing, Nu.Q® Vet Cancer Test for dogs, and Nu.Q® Vet Feline assay for cats.

VolitionRx has a global presence with R&D in Belgium, where it has a lab and manufacturing facility. It also has an innovation laboratory and office in the United States (California and Henderson, Nevada), and offices in London and Singapore. Incorporated in Delaware, its principal executive offices are in Henderson, Nevada. Its operations and partnerships extend across the United States, Europe, and Asia, with the Nu.Q® Vet Cancer Test available in over 20 countries.

VolitionRx's brand reputation is shaped by its mission to improve outcomes through early disease detection and monitoring. Positive events include clinical and commercial progress, strategic partnerships and funding, and innovation in epigenetics. Challenges to its reputation include a "going concern" risk due to financial issues, a NYSE non-compliance notice, and dilution of shares. Overall, VolitionRx is seen as a pioneering company with promising technologies but faces financial hurdles.

VolitionRx Ltd. has a mixed ownership structure including institutional, insider, and retail investors. Institutional investors hold approximately 8.73% to 10.76% of the stock, insiders hold 11.41%, and the general public holds 71.6% to 77.82%. Major institutional owners include Lagoda Investment Management L.P., Vanguard Group Inc, Geode Capital Management LLC, and BlackRock, Inc. Eight Corp Ltd and Cameron John Reynolds are significant individual shareholders.